Lilly, insulin users end $13.5M settlement plan following federal judge’s decision

A set­tle­ment be­tween Eli Lil­ly and in­sulin users has col­lapsed af­ter a fed­er­al judge’s rul­ing that de­nied class cer­ti­fi­ca­tion for the law­suit.

The orig­i­nal set­tle­ment stemmed from a 2017 law­suit in which pa­tients sued the three biggest in­sulin man­u­fac­tur­ers — Eli Lil­ly, No­vo Nordisk and Sanofi — and ac­cused them of “ar­ti­fi­cial and fraud­u­lent in­fla­tion” of their in­sulin prices in the US.

Last May, Lil­ly and the plain­tiffs an­nounced a deal in which Lil­ly would pay $13.5 mil­lion and con­tin­ue to cap out-of-pock­et in­sulin costs at $35 per month for the next four years.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.